Press Releases

 
Press Releases
  Date Title and Summary View
May 23, 2017
NOVATO, Calif., May 23, 2017 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that a Biologics License Application (BLA) submitted to the U.S. Food and Drug Administration (FDA) and a Market...
May 10, 2017
NOVATO, Calif., May 10, 2017 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Emil Kakkis, M.D., Ph.D., the company's Chief Executive Officer, will present at the Bank of America Merrill Lynch Healt...
May 4, 2017
NOVATO, Calif, May 04, 2017 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today reported its financial results and corporate update for the quarter ended March 31, 2017. "We have started the year wi...
Apr 28, 2017
NOVATO, Calif., April 28, 2017 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that it will host a conference call on Thursday, May 4, 2017 at 5pm ET to discuss first quarter 2017 financial r...
Apr 27, 2017
NOVATO, Calif., April 27, 2017 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the initiation of the Phase 3 study of UX007 for the treatment of Glucose Transporter Type 1 Deficiency Syndro...
Apr 18, 2017
Study met primary endpoint of serum phosphorus response and key secondary endpoint of stiffness improvement Ultragenyx to host conference call today at 4:30pm ET to discuss results NOVATO, Calif., LONDON and TOKYO, April 18, 2017 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutic...
Apr 10, 2017
NOVATO, Calif., April 10, 2017 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the appointment of Deborah Dunsire, M.D., to the company's Board of Directors effective April 6, 2017. Dr. Dun...
Apr 6, 2017
NOVATO, Calif. and LONDON, April 06, 2017 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) and Kyowa Kirin International PLC (KKI), a wholly owned subsidiary of Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin), today announced positive 64-week data from a pediatric Phase 2 study of burosumab (KRN23) for the treatment of X...
Mar 22, 2017
NOVATO, Calif., March 22, 2017 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced topline data from the Phase 2 study of UX007 in glucose transporter type-1 deficiency syndrome (Glut1 DS) patients with s...
Mar 2, 2017
NOVATO, Calif., March 02, 2017 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, will present at the following investor conferences: Shalini Sharp, the company's Chief Financia...
Page:
1
... NextLast
= add release to Briefcase